BindingDB logo
myBDB logout

Patent code US10633345

Compile Data Set for Download or QSAR

Found 302 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Plasma kallikrein


(Homo sapiens (Human))
BDBM439471
PNG
(US10633345, Compound 54e | US10633345, Compound 70...)
Show SMILES CN(C(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1)C1CC1
Show InChI InChI=1S/C30H26F4N6O/c1-39(22-9-10-22)28(20-6-2-4-18(12-20)16-35)21-8-11-24(31)25(14-21)37-29(41)26-15-27(30(32,33)34)38-40(26)23-7-3-5-19(13-23)17-36/h2-8,11-15,22,28H,9-10,17,36H2,1H3,(H,37,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416900
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C30H25F4N5O2/c31-24-10-9-22(28(41-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)37-29(40)26-14-27(30(32,33)34)38-39(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28H,7-8,16-17,36H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416902
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((2-chlorophenyl)((...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1Cl)C(F)(F)F
Show InChI InChI=1S/C29H27ClF3N5O/c30-24-10-2-1-9-23(24)27(35-17-18-11-12-18)20-6-4-7-21(14-20)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-3-5-19(13-22)16-34/h1-10,13-15,18,27,35H,11-12,16-17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416773
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O/c30-23-12-11-21(27(35-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27,35H,9-10,16-17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416930
PNG
(1-(3-(Aminomethyl)phenyl)-N-(3-((3-bromo-4-hydroxy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(O)c(Br)c1)C(F)(F)F
Show InChI InChI=1S/C29H27BrF3N5O2/c30-23-13-20(9-10-25(23)39)27(35-16-17-7-8-17)19-4-2-5-21(12-19)36-28(40)24-14-26(29(31,32)33)37-38(24)22-6-1-3-18(11-22)15-34/h1-6,9-14,17,27,35,39H,7-8,15-16,34H2,(H,36,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416906
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H31F4N5O2/c1-45-29-14-12-22-6-2-3-8-25(22)31(29)32(40-19-20-9-10-20)23-11-13-26(35)27(16-23)41-33(44)28-17-30(34(36,37)38)42-43(28)24-7-4-5-21(15-24)18-39/h2-8,11-17,20,32,40H,9-10,18-19,39H2,1H3,(H,41,44)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416794
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C28H25F4N5O2/c29-22-9-8-19(26(39-16-17-6-7-17)20-4-2-10-34-15-20)12-23(22)35-27(38)24-13-25(28(30,31)32)36-37(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,15,17,26H,6-7,14,16,33H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416841
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopro...)
Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H32F3N5O2/c1-44-29-15-14-23-7-2-3-11-27(23)31(29)32(39-20-21-12-13-21)24-8-5-9-25(17-24)40-33(43)28-18-30(34(35,36)37)41-42(28)26-10-4-6-22(16-26)19-38/h2-11,14-18,21,32,39H,12-13,19-20,38H2,1H3,(H,40,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416856
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1O)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-19(27(35-16-17-8-9-17)21-6-1-2-7-25(21)39)13-23(22)36-28(40)24-14-26(29(31,32)33)37-38(24)20-5-3-4-18(12-20)15-34/h1-7,10-14,17,27,35,39H,8-9,15-16,34H2,(H,36,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439557
PNG
(US10633345, Compound 244g)
Show SMILES CC(C)(C)C(=O)NC(CC(C1CC1)c1cccnc1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H36F4N6O2/c1-33(2,3)32(46)42-27(16-25(21-9-10-21)23-7-5-13-40-19-23)22-11-12-26(35)28(15-22)41-31(45)29-17-30(34(36,37)38)43-44(29)24-8-4-6-20(14-24)18-39/h4-8,11-15,17,19,21,25,27H,9-10,16,18,39H2,1-3H3,(H,41,45)(H,42,46)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417003
PNG
((+)-1-(3-carbamimidoylphenyl)-N-(5-((3-cyanophenyl...)
Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C30H25F4N7O/c31-23-10-9-20(27(38-16-17-7-8-17)19-4-1-3-18(11-19)15-35)13-24(23)39-29(42)25-14-26(30(32,33)34)40-41(25)22-6-2-5-21(12-22)28(36)37/h1-6,9-14,17,27,38H,7-8,16H2,(H3,36,37)(H,39,42)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416748
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccn1)C(F)(F)F
Show InChI InChI=1S/C28H27F3N6O/c29-28(30,31)25-15-24(37(36-25)22-8-3-5-19(13-22)16-32)27(38)35-21-7-4-6-20(14-21)26(34-17-18-10-11-18)23-9-1-2-12-33-23/h1-9,12-15,18,26,34H,10-11,16-17,32H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416809
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(2-(cyclopropylamin...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CNC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-16-25(37(36-26)24-11-4-6-19(14-24)17-33)27(38)35-23-10-5-9-21(15-23)28(39,18-34-22-12-13-22)20-7-2-1-3-8-20/h1-11,14-16,22,34,39H,12-13,17-18,33H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416812
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccn1)C(F)(F)F
Show InChI InChI=1S/C28H26F4N6O/c29-21-10-9-19(26(35-16-17-7-8-17)22-6-1-2-11-34-22)13-23(21)36-27(39)24-14-25(28(30,31)32)37-38(24)20-5-3-4-18(12-20)15-33/h1-6,9-14,17,26,35H,7-8,15-16,33H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416823
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Show SMILES CC(C)c1ccc(cc1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C32H34F3N5O/c1-20(2)23-11-13-24(14-12-23)30(37-19-21-9-10-21)25-6-4-7-26(16-25)38-31(41)28-17-29(32(33,34)35)39-40(28)27-8-3-5-22(15-27)18-36/h3-8,11-17,20-21,30,37H,9-10,18-19,36H2,1-2H3,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416840
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((2-(benzyloxy)phen...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1OCc1ccccc1)C(F)(F)F
Show InChI InChI=1S/C36H34F3N5O2/c37-36(38,39)33-20-31(44(43-33)29-13-6-10-26(18-29)21-40)35(45)42-28-12-7-11-27(19-28)34(41-22-24-16-17-24)30-14-4-5-15-32(30)46-23-25-8-2-1-3-9-25/h1-15,18-20,24,34,41H,16-17,21-23,40H2,(H,42,45)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416841
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopro...)
Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H32F3N5O2/c1-44-29-15-14-23-7-2-3-11-27(23)31(29)32(39-20-21-12-13-21)24-8-5-9-25(17-24)40-33(43)28-18-30(34(35,36)37)41-42(28)26-10-4-6-22(16-26)19-38/h2-11,14-18,21,32,39H,12-13,19-20,38H2,1H3,(H,40,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416844
PNG
(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cc2ccccc2c2ccccc12)C(F)(F)F
Show InChI InChI=1S/C37H32F3N5O/c38-37(39,40)34-20-33(45(44-34)28-11-5-7-24(17-28)21-41)36(46)43-27-10-6-9-26(18-27)35(42-22-23-15-16-23)32-19-25-8-1-2-12-29(25)30-13-3-4-14-31(30)32/h1-14,17-20,23,35,42H,15-16,21-22,41H2,(H,43,46)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416847
PNG
(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Show SMILES CN(C)c1ccc(C(NCC2CC2)c2cccc(NC(=O)c3cc(nn3-c3cccc(CN)c3)C(F)(F)F)c2)c2ccccc12
Show InChI InChI=1S/C35H35F3N6O/c1-43(2)30-16-15-29(27-11-3-4-12-28(27)30)33(40-21-22-13-14-22)24-8-6-9-25(18-24)41-34(45)31-19-32(35(36,37)38)42-44(31)26-10-5-7-23(17-26)20-39/h3-12,15-19,22,33,40H,13-14,20-21,39H2,1-2H3,(H,41,45)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416850
PNG
(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Show SMILES CCCOc1ccc(cc1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C32H34F3N5O2/c1-2-15-42-27-13-11-23(12-14-27)30(37-20-21-9-10-21)24-6-4-7-25(17-24)38-31(41)28-18-29(32(33,34)35)39-40(28)26-8-3-5-22(16-26)19-36/h3-8,11-14,16-18,21,30,37H,2,9-10,15,19-20,36H2,1H3,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416853
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccc(N)c1)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-23-10-9-20(27(40-16-17-7-8-17)19-4-2-5-21(35)12-19)13-24(23)36-28(39)25-14-26(29(31,32)33)37-38(25)22-6-1-3-18(11-22)15-34/h1-6,9-14,17,27H,7-8,15-16,34-35H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439407
PNG
(US10633345, Compound 52h | US10633345, Compound 71...)
Show SMILES CN(C(c1ccc(cc1)C#N)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1)C1CC1
Show InChI InChI=1S/C30H26F4N6O/c1-39(22-10-11-22)28(20-7-5-18(16-35)6-8-20)21-9-12-24(31)25(14-21)37-29(41)26-15-27(30(32,33)34)38-40(26)23-4-2-3-19(13-23)17-36/h2-9,12-15,22,28H,10-11,17,36H2,1H3,(H,37,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416871
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(benzo[d][1,3]dioxo...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc2OCOc12)C(F)(F)F
Show InChI InChI=1S/C30H28F3N5O3/c31-30(32,33)26-14-24(38(37-26)22-7-1-4-19(12-22)15-34)29(39)36-21-6-2-5-20(13-21)27(35-16-18-10-11-18)23-8-3-9-25-28(23)41-17-40-25/h1-9,12-14,18,27,35H,10-11,15-17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416902
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((2-chlorophenyl)((...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1Cl)C(F)(F)F
Show InChI InChI=1S/C29H27ClF3N5O/c30-24-10-2-1-9-23(24)27(35-17-18-11-12-18)20-6-4-7-21(14-20)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-3-5-19(13-22)16-34/h1-10,13-15,18,27,35H,11-12,16-17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416843
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((4-aminophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(N)cc1)C(F)(F)F
Show InChI InChI=1S/C29H29F3N6O/c30-29(31,32)26-15-25(38(37-26)24-6-1-3-19(13-24)16-33)28(39)36-23-5-2-4-21(14-23)27(35-17-18-7-8-18)20-9-11-22(34)12-10-20/h1-6,9-15,18,27,35H,7-8,16-17,33-34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416843
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((4-aminophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(N)cc1)C(F)(F)F
Show InChI InChI=1S/C29H29F3N6O/c30-29(31,32)26-15-25(38(37-26)24-6-1-3-19(13-24)16-33)28(39)36-23-5-2-4-21(14-23)27(35-17-18-7-8-18)20-9-11-22(34)12-10-20/h1-6,9-15,18,27,35H,7-8,16-17,33-34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416897
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-23-9-8-20(28(40,11-10-18-6-7-18)21-4-2-12-35-17-21)14-24(23)36-27(39)25-15-26(29(31,32)33)37-38(25)22-5-1-3-19(13-22)16-34/h1-5,8-9,12-15,17-18,40H,6-7,10-11,16,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439471
PNG
(US10633345, Compound 54e | US10633345, Compound 70...)
Show SMILES CN(C(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1)C1CC1
Show InChI InChI=1S/C30H26F4N6O/c1-39(22-9-10-22)28(20-6-2-4-18(12-20)16-35)21-8-11-24(31)25(14-21)37-29(41)26-15-27(30(32,33)34)38-40(26)23-7-3-5-19(13-23)17-36/h2-8,11-15,22,28H,9-10,17,36H2,1H3,(H,37,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416747
PNG
(1-(3-(Aminomethyl)phenyl)-N-(5-((cyclopropylmethox...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H26F4N4O2/c30-23-12-11-21(27(39-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)35-28(38)25-15-26(29(31,32)33)36-37(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27H,9-10,16-17,34H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416972
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N-(5-((bis(cyclopro...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N(CC1CC1)CC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C33H33F4N5O/c34-27-14-13-25(31(24-6-2-1-3-7-24)41(19-21-9-10-21)20-22-11-12-22)16-28(27)39-32(43)29-17-30(33(35,36)37)40-42(29)26-8-4-5-23(15-26)18-38/h1-8,13-17,21-22,31H,9-12,18-20,38H2,(H,39,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416973
PNG
((+)-N5-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(cc1)C#N)C(N)=O
Show InChI InChI=1S/C31H30FN7O2/c32-25-11-10-23(31(36,13-12-19-4-5-19)22-8-6-20(17-33)7-9-22)15-26(25)37-30(41)28-16-27(29(35)40)38-39(28)24-3-1-2-21(14-24)18-34/h1-3,6-11,14-16,19H,4-5,12-13,18,34,36H2,(H2,35,40)(H,37,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416988
PNG
((+)-N-(3-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(N)(CCC1CC1)c1ccc(cc1)C#N)C(F)(F)F
Show InChI InChI=1S/C31H29F3N6O/c32-31(33,34)28-17-27(40(39-28)26-6-1-3-22(15-26)19-36)29(41)38-25-5-2-4-24(16-25)30(37,14-13-20-7-8-20)23-11-9-21(18-35)10-12-23/h1-6,9-12,15-17,20H,7-8,13-14,19,36-37H2,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416992
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Show SMILES CS(=O)(=O)NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H30F4N6O3S/c1-44(42,43)39-29(12-9-19-5-6-19,21-10-13-36-14-11-21)22-7-8-24(31)25(16-22)37-28(41)26-17-27(30(32,33)34)38-40(26)23-4-2-3-20(15-23)18-35/h2-4,7-8,10-11,13-17,19,39H,5-6,9,12,18,35H2,1H3,(H,37,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416996
PNG
((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C31H28F4N6O/c32-25-10-9-23(30(38,12-11-19-7-8-19)22-5-1-3-20(13-22)17-36)15-26(25)39-29(42)27-16-28(31(33,34)35)40-41(27)24-6-2-4-21(14-24)18-37/h1-6,9-10,13-16,19H,7-8,11-12,18,37-38H2,(H,39,42)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417026
PNG
((+-)-1-(3-(aminomethyl)phenyl)-N5-(5-((cyclopropyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(N)=O
Show InChI InChI=1S/C29H29FN6O2/c30-23-12-11-21(27(33-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)34-29(38)26-15-25(28(32)37)35-36(26)22-8-4-5-19(13-22)16-31/h1-8,11-15,18,27,33H,9-10,16-17,31H2,(H2,32,37)(H,34,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416730
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-ph...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(CCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C30H29F3N4O/c31-30(32,33)28-18-27(37(36-28)25-11-4-6-21(16-25)19-34)29(38)35-24-10-5-9-23(17-24)26(15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,16-18,20,26H,12-15,19,34H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416742
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(C(NCC2CC2)c2ccccc2)c1F)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O/c30-26-22(27(35-17-18-12-13-18)20-7-2-1-3-8-20)10-5-11-23(26)36-28(39)24-15-25(29(31,32)33)37-38(24)21-9-4-6-19(14-21)16-34/h1-11,14-15,18,27,35H,12-13,16-17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416745
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1nccs1)C(F)(F)F
Show InChI InChI=1S/C26H24F3N5O2S/c27-26(28,29)22-13-21(34(33-22)20-6-1-3-17(11-20)14-30)24(35)32-19-5-2-4-18(12-19)23(25-31-9-10-37-25)36-15-16-7-8-16/h1-6,9-13,16,23H,7-8,14-15,30H2,(H,32,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439347
PNG
(US10633345, Compound 41e | US10689346, Compound 41...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O/c30-29(31,32)26-16-25(37(36-26)24-11-4-6-20(14-24)17-33)28(38)35-23-10-5-9-22(15-23)27(34-18-19-12-13-19)21-7-2-1-3-8-21/h1-11,14-16,19,27,34H,12-13,17-18,33H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416784
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C28H26F4N6O/c29-22-9-8-19(26(35-15-17-6-7-17)20-4-2-10-34-16-20)12-23(22)36-27(39)24-13-25(28(30,31)32)37-38(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,16-17,26,35H,6-7,14-15,33H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416786
PNG
(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc2ccccc12)C(F)(F)F
Show InChI InChI=1S/C33H30F3N5O/c34-33(35,36)30-18-29(41(40-30)26-11-3-6-22(16-26)19-37)32(42)39-25-10-4-9-24(17-25)31(38-20-21-14-15-21)28-13-5-8-23-7-1-2-12-27(23)28/h1-13,16-18,21,31,38H,14-15,19-20,37H2,(H,39,42)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416791
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(cc1)S(N)(=O)=O)C(F)(F)F
Show InChI InChI=1S/C29H29F3N6O3S/c30-29(31,32)26-15-25(38(37-26)23-6-1-3-19(13-23)16-33)28(39)36-22-5-2-4-21(14-22)27(35-17-18-7-8-18)20-9-11-24(12-10-20)42(34,40)41/h1-6,9-15,18,27,35H,7-8,16-17,33H2,(H,36,39)(H2,34,40,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416799
PNG
(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(cc1)-c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C35H32F3N5O/c36-35(37,38)32-20-31(43(42-32)30-11-4-6-24(18-30)21-39)34(44)41-29-10-5-9-28(19-29)33(40-22-23-12-13-23)27-16-14-26(15-17-27)25-7-2-1-3-8-25/h1-11,14-20,23,33,40H,12-13,21-22,39H2,(H,41,44)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416810
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1F)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O/c30-24-10-2-1-9-23(24)27(35-17-18-11-12-18)20-6-4-7-21(14-20)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-3-5-19(13-22)16-34/h1-10,13-15,18,27,35H,11-12,16-17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416813
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((10-chloroanthrace...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1c2ccccc2c(Cl)c2ccccc12)C(F)(F)F
Show InChI InChI=1S/C37H31ClF3N5O/c38-34-29-13-3-1-11-27(29)33(28-12-2-4-14-30(28)34)35(43-21-22-15-16-22)24-8-6-9-25(18-24)44-36(47)31-19-32(37(39,40)41)45-46(31)26-10-5-7-23(17-26)20-42/h1-14,17-19,22,35,43H,15-16,20-21,42H2,(H,44,47)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416815
PNG
(1-(3-(Aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1nccs1)C(F)(F)F
Show InChI InChI=1S/C26H24F4N6OS/c27-19-7-6-17(23(25-32-8-9-38-25)33-14-15-4-5-15)11-20(19)34-24(37)21-12-22(26(28,29)30)35-36(21)18-3-1-2-16(10-18)13-31/h1-3,6-12,15,23,33H,4-5,13-14,31H2,(H,34,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439400
PNG
(US10633345, Compound 119e | US10689346, Compound 1...)
Show SMILES COc1ccccc1C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H30F3N5O2/c1-40-26-11-3-2-10-24(26)28(35-18-19-12-13-19)21-7-5-8-22(15-21)36-29(39)25-16-27(30(31,32)33)37-38(25)23-9-4-6-20(14-23)17-34/h2-11,14-16,19,28,35H,12-13,17-18,34H2,1H3,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439402
PNG
(US10633345, Compound 102b | US10689346, Compound 1...)
Show SMILES CN(C(c1cccc(N)c1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1)C1CC1
Show InChI InChI=1S/C29H29F3N6O/c1-37(23-11-12-23)27(19-6-3-8-21(34)14-19)20-7-4-9-22(15-20)35-28(39)25-16-26(29(30,31)32)36-38(25)24-10-2-5-18(13-24)17-33/h2-10,13-16,23,27H,11-12,17,33-34H2,1H3,(H,35,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416874
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(((1-hydroxybutan-2...)
Show SMILES CCC(CO)NC(c1ccccc1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C29H30F3N5O2/c1-2-22(18-38)34-27(20-9-4-3-5-10-20)21-11-7-12-23(15-21)35-28(39)25-16-26(29(30,31)32)36-37(25)24-13-6-8-19(14-24)17-33/h3-16,22,27,34,38H,2,17-18,33H2,1H3,(H,35,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416884
PNG
(1-(3-(Aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Show SMILES Cc1ccccc1C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H30F3N5O/c1-19-6-2-3-11-25(19)28(35-18-20-12-13-20)22-8-5-9-23(15-22)36-29(39)26-16-27(30(31,32)33)37-38(26)24-10-4-7-21(14-24)17-34/h2-11,14-16,20,28,35H,12-13,17-18,34H2,1H3,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...


US Patent US10633345 (2020)

More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 302 total )  |  Next  |  Last  >>
* indicates data uncertainty>20%